First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study).
Renaud DescourtLaurent GreillierMaurice PerolCharles RicordelJean-Bernard AuliacLionel FalcheroRadj GervaisRémi VeillonSabine VieillotFlorian GuisierMarie MarcqGrégoire JusteauLaurence Bigay-GameMarie BernardiPierre FournelHélène DoubreJulian PinsolleKarim AmraneChristos ChouaidChantal DecroisettePublished in: Cancer immunology, immunotherapy : CII (2022)
In this large multicenter cohort, nearly 20% of patients initiating pembrolizumab therapy for advanced NSCLC had cerebral metastases. There was no significant difference in response rates, PFS and OS between patients with and without brain metastases.